Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
IPO Year: 2014
Exchange: NASDAQ
Website: ardelyx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $11.00 → $5.50 | Buy → Neutral | H.C. Wainwright |
| 7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
| 4/5/2024 | $14.00 | Outperform | Leerink Partners |
| 12/18/2023 | $12.00 | Strong Buy | Raymond James |
| 9/7/2023 | $9.00 | Buy | H.C. Wainwright |
| 8/25/2023 | $5.00 → $10.00 | Neutral → Overweight | Cantor Fitzgerald |
| 3/3/2023 | $3.00 → $6.00 | Neutral → Outperform | Wedbush |
| 11/17/2022 | $3.00 → $8.00 | Neutral → Overweight | Piper Sandler |
| 5/6/2022 | $7.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 3/2/2022 | $1.00 → $5.00 | Hold → Buy | Jefferies |
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
8-K - ARDELYX, INC. (0001437402) (Filer)
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
8-K - ARDELYX, INC. (0001437402) (Filer)
144 - ARDELYX, INC. (0001437402) (Subject)
S-8 - ARDELYX, INC. (0001437402) (Filer)
10-Q - ARDELYX, INC. (0001437402) (Filer)
8-K - ARDELYX, INC. (0001437402) (Filer)
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales revenue of greater than $1 Billion Company announces peak U.S. net XPHOZAH sales revenue of $750 million Company finishes 2024 with approximately $250 million in cash, cash equivalents and investments (unaudited) WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update on the co
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days fo
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New York City. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentation
WALTHAM, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today confirmed that Judge Beryl Howell from the U.S. District Court for Washington, D.C. has granted defendants' motion to dismiss the lawsuit filed by Ardelyx, the American Association of Kidney Patients (AAKP) and the National Minority Quality Forum (NMQF), permitting the Centers for Medicare and Medicaid Services (CMS) to proceed with its plan to include XPHOZAH® (tenapanor) and other oral-only phosphate lowering therapies (PLTs) in the End-
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ar
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov
Ninety percent of survey participants reported "some" or "significant" negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partnership with Health Union, were presented at the American College of Gastroenterology's (ACG) Annual Scientific Meeting & Postgraduate Course, currently taking place in Philadelphia. Developed as an
WALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the American Society of Nephrology's (ASN) Kidney Week, currently taking place in San Diego. Ardelyx is also hosting an Exhibitor Spotlight discussing hyperphosphatemia management. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Adminis
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx's director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroe
WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
FREMONT, Calif. and WALTHAM, Mass., March 15, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the appointment of Muna Bhanji, R.Ph, to the company's board of directors, effective March 11, 2021. Ardelyx also announced that long time director, Gordon Ringold, Ph.D., stepped down from the board effective March 11, 2021. "We are thrilled to welcome Muna to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "She is a veteran leader recognized for developing global strategies in drug
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
H.C. Wainwright downgraded Ardelyx from Buy to Neutral and set a new price target of $5.50 from $11.00 previously
Piper Sandler downgraded Ardelyx from Overweight to Neutral and set a new price target of $7.00 from $15.00 previously
Leerink Partners initiated coverage of Ardelyx with a rating of Outperform and set a new price target of $14.00
Raymond James initiated coverage of Ardelyx with a rating of Strong Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of Ardelyx with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald upgraded Ardelyx from Neutral to Overweight and set a new price target of $10.00 from $5.00 previously
Wedbush upgraded Ardelyx from Neutral to Outperform and set a new price target of $6.00 from $3.00 previously
Piper Sandler upgraded Ardelyx from Neutral to Overweight and set a new price target of $8.00 from $3.00 previously
Cantor Fitzgerald downgraded Ardelyx from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously
Jefferies upgraded Ardelyx from Hold to Buy and set a new price target of $5.00 from $1.00 previously
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail
IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov
WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the I
IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. "In the second quarter, Ardelyx demonstrated our commitment to our mission and to
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the In
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH® (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) En
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. "The first quarter of 2024 mar
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, ending FY 2023 with $2.5 million in net product sales revenue Company ends FY 2023 with $184.3 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2023 financial results and provide a business update. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under t
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-4) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 211801, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-3) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 05/19/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-2) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 03/05/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling